Cellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays dropped their price target on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th.

Cellectis Price Performance

Shares of NASDAQ CLLS opened at $1.88 on Thursday. Cellectis has a twelve month low of $1.70 and a twelve month high of $3.77. The firm has a market cap of $104.50 million, a P/E ratio of -1.45 and a beta of 3.10. The company has a 50 day moving average of $1.98 and a 200 day moving average of $2.22. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The business had revenue of $18.05 million during the quarter, compared to analysts’ expectations of $5.00 million. During the same quarter in the prior year, the firm earned ($0.31) EPS. As a group, research analysts expect that Cellectis will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CLLS. Principal Financial Group Inc. increased its position in shares of Cellectis by 2.9% during the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares during the last quarter. XTX Topco Ltd bought a new position in Cellectis in the second quarter worth approximately $29,000. First Affirmative Financial Network purchased a new position in shares of Cellectis during the 3rd quarter worth $45,000. Finally, Long Focus Capital Management LLC boosted its stake in shares of Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares during the last quarter. Institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.